Louis J. Maher
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Louis J. Maher.
The Journal of Clinical Endocrinology and Metabolism | 2015
Paraskevi Xekouki; Eva Szarek; Petra Bullova; Alessio Giubellino; Martha Quezado; Spyridon A. Mastroyannis; Panagiotis Mastorakos; Christopher A. Wassif; Margarita Raygada; Nadia Rentia; Louis Dye; Antony Cougnoux; Deloris E. Koziol; Maria de la Luz Sierra; Charalampos Lyssikatos; Elena Belyavskaya; Carl D. Malchoff; Jessica Moline; Charis Eng; Louis J. Maher; Karel Pacak; Maya Lodish; Constantine A. Stratakis
CONTEXT Germline mutations in genes coding succinate dehydrogenase (SDH) subunits A, B, C, and D have been identified in familial paragangliomas (PGLs)/pheochromocytomas (PHEOs) and other tumors. We described a GH-secreting pituitary adenoma (PA) caused by SDHD mutation in a patient with familial PGLs. Additional patients with PAs and SDHx defects have since been reported. DESIGN We studied 168 patients with unselected sporadic PA and with the association of PAs, PGLs, and/or pheochromocytomas, a condition we named the 3P association (3PAs) for SDHx germline mutations. We also studied the pituitary gland and hormonal profile of Sdhb(+/-) mice and their wild-type littermates at different ages. RESULTS No SDHx mutations were detected among sporadic PA, whereas three of four familial cases were positive for a mutation (75%). Most of the SDHx-deficient PAs were either prolactinomas or somatotropinomas. Pituitaries of Sdhb(+/-) mice older than 12 months had an increased number mainly of prolactin-secreting cells and several ultrastructural abnormalities such as intranuclear inclusions, altered chromatin nuclear pattern, and abnormal mitochondria. Igf-1 levels of mutant mice tended to be higher across age groups, whereas Prl and Gh levels varied according to age and sex. CONCLUSION The present study confirms the existence of a new association that we termed 3PAs. It is due mostly to germline SDHx defects, although sporadic cases of 3PAs without SDHx defects also exist. Using Sdhb(+/-) mice, we provide evidence that pituitary hyperplasia in SDHx-deficient cells may be the initial abnormality in the cascade of events leading to PA formation.
PLOS ONE | 2015
Yeng F. Her; Molly Nelson-Holte; Louis J. Maher
Familial paraganglioma (PGL) is a rare neuroendocrine cancer associated with defects in the genes encoding the subunits of succinate dehydrogenase (SDH), a tricarboxylic acid (TCA) cycle enzyme. For unknown reasons, a higher prevalence of PGL has been reported for humans living at higher altitude, with increased disease aggressiveness and morbidity. In this study, we evaluate the effects of oxygen on epigenetic changes due to succinate accumulation in three SDH loss cell culture models. We test the hypothesis that the mechanism of α-ketoglutarate (α-KG)-dependent dioxygenase enzymes explains the inhibitory synergy of hypoxia and succinate accumulation. We confirm that SDH loss leads to profound succinate accumulation. We further show that hypoxia and succinate accumulation synergistically inhibit α-KG-dependent dioxygenases leading to increased stabilization of transcription factor HIF1α, HIF2α, and hypermethylation of histones and DNA. Increasing oxygen suppresses succinate inhibition of α-KG-dependent dioxygenases. This result provides a possible explanation for the association between hypoxia and PGL, and suggests hyperoxia as a potential novel therapy.
Nucleic Acid Therapeutics | 2016
Estefanía Mondragón; Louis J. Maher
Transcription factors (TFs) are DNA-binding proteins that play critical roles in regulating gene expression. These proteins control all major cellular processes, including growth, development, and homeostasis. Because of their pivotal role, cells depend on proper TF function. It is, therefore, not surprising that TF deregulation is linked to disease. The therapeutic drug targeting of TFs has been proposed as a frontier in medicine. RNA aptamers make interesting candidates for TF modulation because of their unique characteristics. The products of in vitro selection, aptamers are short nucleic acids (DNA or RNA) that bind their targets with high affinity and specificity. Aptamers can be expressed on demand from transgenes and are intrinsically amenable to recognition by nucleic acid-binding proteins such as TFs. In this study, we review several natural prokaryotic and eukaryotic examples of RNAs that modulate the activity of TFs. These examples include 5S RNA, 6S RNA, 7SK, hepatitis delta virus-RNA (HDV-RNA), neuron restrictive silencer element (NRSE)-RNA, growth arrest-specific 5 (Gas5), steroid receptor RNA activator (SRA), trophoblast STAT utron (TSU), the 3′ untranslated region of caudal mRNA, and heat shock RNA-1 (HSR1). We then review examples of unnatural RNA aptamers selected to inhibit TFs nuclear factor-kappaB (NF-κB), TATA-binding protein (TBP), heat shock factor 1 (HSF1), and runt-related transcription factor 1 (RUNX1). The field of RNA aptamers for DNA-binding proteins continues to show promise.
bioRxiv | 2015
John A. Smestad; Louis J. Maher
Putative G-quadruplex-forming sequences (PQS) have long been implicated in regulation of DNA replication and transcription, though their actual roles are unknown. To gain insight into potential PQS transcriptional function, we map and analyze PQS motifs in promoters of genes differentially-expressed in Bloom Syndrome (BS) and Werner Syndrome (WS), two human genetic disorders resulting in loss of PQS-interacting RecQ helicases. Non-B-DNA structures at PQS might be stabilized in these syndromes. For BS and WS we demonstrate that PQS promoter abundance is generally higher in down-regulated genes and lower in up-regulated genes, and show that these effects are position-dependent. To interpret these correlations we determined genome-wide PQS correlations with transcription using epigenetic information to predict gene expression. We report that 33% and 35% of analyzed PQS positions in promoter antisense and sense strands, respectively, displayed statistically-significant correlation with gene expression. Of these statistically-significant positions, 100% and 84% on antisense and sense strands, respectively, were correlated with reduced expression. This suggests that promoter PQS repress transcription. Finally, we report neural network clustering analysis of PQS motifs to demonstrate that genes differentially-expressed in BS and WS are significantly biased in their PQS motifs, suggesting an unappreciated biological relationship between PQS, RecQ helicases, and transcription. REVIEWER LINKS TO DEPOSITED DATA ftp://www.jsmes.net/PQS_Genomics
Expert Opinion on Biological Therapy | 2018
Maria K. Perwein; John A. Smestad; Arthur E. Warrington; Robin M. Heider; Mark W. Kaczor; Louis J. Maher; Bharath Wootla; Ahmad Kunbaz; Moses Rodriguez
ABSTRACT Introduction: Multiple sclerosis (MS) is a chronic and progressive inflammatory demyelinating disease of the human central nervous system (CNS) and is the most common disabling neurological condition in young adults, resulting in severe neurological defects. No curative or long-term progression-inhibiting therapy has yet been developed. However, recent investigation has revealed potential strategies that do not merely modulate potentially pathogenic autoimmune responses, but stimulate remyelination within CNS lesions. Areas covered: We discuss the history and development of natural human IgM-isotype immunoglobulins (HIgMs) and recently-identified aptamer-conjugates that have been shown to enhance endogenous myelin repair in animal models of demyelination by acting on myelin-producing oligodendrocytes (OLs) or oligodendrocyte progenitor cells (OPCs) within CNS lesions. We also discuss future development aims and applications for these important novel technologies. Expert opinion: Aptamer conjugate Myaptavin-3064 and recombinant human IgM-isotype antibody rHIgM22 regenerate CNS myelin, thereby reducing axonal degeneration and offering the potential of recovery from MS relapses, reversal of disability and prevention of disease progression. Advancement of these technologies into the clinic for MS treatment is therefore a top priority. It remains unclear to what extent the therapeutic modalities of remyelinating antibodies and aptamers may synergize with other currently-approved therapies to yield enhanced therapeutic effects.
Gastroenterology | 2017
Yujiro Hayashi; Yoshitaka Toyomasu; Siva Arumugam Saravanaperumal; Michael R. Bardsley; John A. Smestad; Andrea Lorincz; Seth T. Eisenman; Gianluca Cipriani; Molly H. Nelson Holte; Fatimah J. Al Khazal; Sabriya A. Syed; Gabriella B. Gajdos; Kyoung Moo Choi; Gary J. Stoltz; Katie E. Miller; Michael L. Kendrick; Brian P. Rubin; Simon J. Gibbons; Adil E. Bharucha; David R. Linden; Louis J. Maher; Gianrico Farrugia; Tamas Ordog
Archive | 2011
Louis J. Maher; Emily H. Smith; Emily M. Rueter; Nicole A. Becker; John P. Bida; Molly Nelson-Holte; José Ignacio Piruat Palomo; Paula García-Flores; José López-Barneo; Jan M. van Deursen
Cancer Research | 2018
John A. Smestad; Louis J. Maher
Gastroenterology | 2017
Siva Arumugam Saravanaperumal; Yujiro Hayashi; Gabriella B. Gajdos; Sabriya A. Syed; Chad R. Clark; John A. Smestad; Molly H. Nelson Holte; Fatimah J. Al Khazal; Katie E. Miller; David R. Linden; Michael L. Kendrick; Travis J. McKenzie; Todd A. Kellogg; Krutika Satish Gaonkar; Huihuang Yan; Saurabh Baheti; Zhifu Sun; Dieter Saur; Gianrico Farrugia; Jeong Heon Lee; Louis J. Maher; Tamas Ordog
Gastroenterology | 2016
Yujiro Hayashi; Yoshitaka Toyomasu; Molly H. Nelson Holte; Siva Arumugam Saravanaperumal; Sabriya A. Syed; Gabriella B. Gajdos; Michael L. Kendrick; Gianrico Farrugia; Louis J. Maher; Tamas Ordog